NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Doc, the only part I differ with from your post is the section called out below. IMO, I don’t think any “treatment” induced psPD in the SOC patients caused them to cross over to receive DCVax-L. Instead, I think the SOC patients truly evented (remember, they’d been screened for chemo/rad induced psPD), crossed over and received DCVax-L, and “lived longer” (LL’s words). And instead, the treatment arm pseudoprogressed very quickly on DCVax-L, and, using the crappy old criteria, were determined to have truly progressed (which they hadn’t, but this ruined any chance of PFS being used in any request for accelerated approval).

I often lament that the criteria wasn’t upgraded in 2012 when they changed the trial from a P2 to a P3. Cie la vie.

treatment induced pseudoprogression leading to SOC/placebo patients crossing over before true progression and actually becoming more like best scenario treatment arm patients - Doc